MEFENAMIC CAPSULE
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
10-04-2019
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
MEFENAMIC ACID
から入手可能:
AA PHARMA INC
ATCコード:
M01AG01
INN（国際名）:
MEFENAMIC ACID
投薬量:
250MG
医薬品形態:
CAPSULE
構図:
MEFENAMIC ACID 250MG
投与経路:
ORAL
パッケージ内のユニット:
100/500
処方タイプ:
Prescription
治療領域:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
製品概要:
Active ingredient group (AIG) number: 0102336001; AHFS:
認証ステータス:
APPROVED
承認日:
2010-12-08
製品の特徴
Page 1 of 32
_ _
PRESCRIBING INFORMATION
PRODUCT MONOGRAPH
PR
MEFENAMIC
MEFENAMIC ACID CAPSULES
250 MG
USP
ANALGESIC
AA PHARMA INC.
1165 CREDITSTONE ROAD, UNIT #1
VAUGHAN, ONTARIO
L4K 4N7
DATE OF REVISION:
April 10, 2019
CONTROL NO.: 226522
Page 2 of 32
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
15
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND ADMINISTRATION
.............................................................................
19
OVERDOSAGE
...............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
......................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
22
PHARMACEUTICAL INFORMATION
.........................................................................
22
CLINICAL TRIALS
.........................................................................................................
23
DETAILED PHARMA
完全なドキュメントを読む
